Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01600716 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
NCT01600716 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 144 participants.
The verdict
NCT01600716, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
Interventions
- BIOLOGICAL OnabotulinumtoxinA
- DRUG Placebo (Normal Saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2012-06-13 |
| Est. Completion | 2015-03-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01600716
The ClinicalTrials.gov registry entry for NCT01600716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.
NCT01600716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01600716 about?
NCT01600716 is a clinical study titled "Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)". This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
What is the current status of trial NCT01600716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2012-06-13. Estimated completion is 2015-03-27.
What interventions are being tested in trial NCT01600716?
The interventions under investigation include: OnabotulinumtoxinA (BIOLOGICAL), Placebo (Normal Saline) (DRUG).
Who is sponsoring clinical trial NCT01600716?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.